

Quality of Care Program Mortality Review

Overview

- Discussions about mortality review have occurred in the NYS
 Quality of Care Advisory Committee for over seven years with
 input from national experts.
- A review of mortality among people with HIV is to be included in the 2018 review of care provided in 2017

 A subcommittee, comprised of members of the QAC and CAC, has been meeting since April to develop the review process



Scope of Review

- Mortality review will include:
 - Reporting of deaths among PLWH in an organization (includes deaths on site and deaths of established patients)
 - Identification of deaths attributable to HIV and analysis of specific causes of death
 - Emphasis placed on identifying modifiable factors associated with deaths of PLWH
 - Facilities will submit a plan for addressing these factors
 - Special focus will be given to access to care/care coordination issues, including access to specialty care, that may have contributed to death
- The average number of reviews per site will be approximately 9 (range 0-66*) based on preliminary 2016 eHIVQUAL results on number of decedents/site

^{*}An HIV program reporting on other hospital departments, including ED, in their organization

Coding Causes of Death in HIV (CoDe)

- Developed by the University of Copenhagen to standardize approach to collecting data on cause of death and reviewing deaths.
- Mortality Subcommittee CoDe Subgroup has adapted the CoDe chart abstraction tool and instructions for using the tool for use in NYS
 - Adaptations of the CoDe tool by the San Francisco Department of Public Health have also been considered



New York State Mortality Data Collection From

Date of death: (MM/DD/YYYY)		
1. Active Patient: ☐ Yes ☐ No	2. Died at Institution: ☐ Yes ☐ No If no, facility of death	
3. a. Patient's zip code c. Zip code of facility where patient die	b. Zip code of facility where patient is active d (if different)	_



Section 1: Background Demographics

A. Year of birth (yyyy) B. Year of HIV diagnosis (yyyy)		
C. Sex assigned at birth: ☐ male ☐ female ☐ intersex ☐ unknown		
D . Current gender identity: \square male \square female \square trans male \square trans female		
\square gender non-conforming/non-binary \square other \square unknown		
E. Race and ethnicity: \square Asian \square Black, non-Hispanic \square Hispanic \square Native Ame	ericar	n/Alaskan Native
\square Native Hawaiian/Pacific Islander \square White, non-Hispanic \square Other (please speci	ify)
unknown		
F. Country of Birth: U.S. Uther (please specify	_)	\square unknown
G. Preferred Language: ☐ English ☐ French or Creole ☐ Spanish ☐ ASL		
Other (please specify) unknown		
	5	STATE OF DEPARTMENT

Background Demographics Cont.

H. Risk: ☐MSM ☐	IDU □MSM-IDU □	Heterosexual Heterosexual-IDU Perinatal		
☐ Not reported ☐ Ot	Not reported Other Ounknown			
I. Height (cm):	J. Weight (kg): (most recent before death)	Date / / (MM/DD/YYYY weight measured)		
	Weight (kg) : (1 year prior to death)	Date :(MM/DD/YYYY weight measured)		
K. Insurance at time of death (select all that apply)				
□ Private Managed Ca	re or Commercial Covera	ge 🏻 Medicaid Managed Care; plan name:		
Medicare		HIV SNP; plan name:		
Medicaid		Uninsured		
ADAP Plus Unknown				
ADAP				

Section 2: Data Sources

Section 3: Risk Factors

A. Ongoing risk factors:

I. Cigarette smoking			
	a.	Current (within last 6 months)	
	b.	Past (6 -12 months) 🗆 Yes 🗆 No 🗆 Unknown	
	c.	Past (> 12 months) ☐ Yes ☐ No ☐ Unknown	
	d.	Never 🗆 Yes 🗆 No 🗆 Unknown	
2.	Exc	essive alcohol consumption	
	a.	Current (within last 6 months)	
	b.	Past (6 -12 months)	
	c.	Past (> 12 months)	
	d.	Never Tyes No Unknown	
3.	Acti	ve substance use	
	a.	Current (within last 6 months)	
	b.	Past (6 -12 months)	
	c.	Past (> 12 months) ☐ Yes ☐ No ☐ Unknown	
	d.	Never ☐ Yes ☐ No ☐ Unknown	



Risk Factors Cont.

3.1 If substance use occurred in	n the past 6 months, rou	te (select all that apply)	
☐IDU ☐Sniffing ☐Inge	stion Skin Popping	Smoking Unknown	
3.2 If substance use occurred, o	circle all of the types of o	drugs used, in the past 6 months, regar	dless of
l. Amphetamines	Benzodiazepines	3. Cocaine/crack	
1. Crystal methamphetamine	5. Ecstasy	6. Hallucinogens (PCP, LSD, other)	
7. Heroin	8. Inhalants (glue, nitro	ous oxide)	
3. Ketamine 10. Prescription opioids (Vicodin, Codeine)			
5. Other substance(s)			
I. Opioid Use Disorder Treatme a. Current (within last 6 mo b. Past (6 months or more) c. Never Yes	onths)	Unknown	
c. Never∟ res ∟ No	□ Unknown		ne h

Risk Factors Cont.

	ring situation in 12 months prior to death (select all that apply and identify the most recent with an terisks)
a.	Stable Permanent Housing
b.	Temporary Housing
C .	Unstable Housing
d.	Homeless
е.	Unknown
Inc	carcerated within 12 months prior to death \square Yes \square No \square Unknown
Ev	er received hospice care 🗌 Yes 🔝 No 🗀 Unknown
Ex	perienced challenges accessing care due to transportation barriers in the 12 months prior to death
Yes	s 🗆 No 🗆 Unknown
	as a. b. d. e. Ev

Section 4: Co-morbidities

A. Ongoing chronic conditions:	
1. Hypertension ☐ Yes ☐ No ☐ Unknown	
• Controlled ☐ Yes ☐ No ☐ Unknown	
Blood pressure closest to time of death in an outpatient setting	Date/_/ MM/ DD/ YYYY
2. Diabetes mellitus ☐ Yes ☐ No ☐ Unknown	
■ Controlled ☐ Yes ☐ No ☐ Unknown	
Hemoglobin A1c closest to time of death in an outpatient setting	Date// MM/ DD/ YYYY
3. Dyslipidemia □ Yes □ No □ Unknown	
■ Controlled ☐ Yes ☐ No ☐ Unknown	

B. Cardiovascular disease (myocardial infarction, stroke, invasive cardiovascular procedure, angina, arrhythmia, or peripheral arterial disease)			
a. Current			
b. Past (resolved)			
c. No indication from medical record or provider \square			
C. History of depression			
a. Within past 12 months			
b. Ever			
c. No indication from medical record or provider:			
Evidence of having received clinical care or medication for depression: \square Yes \square No \square Unknown			
D. Bipolar Disorder ☐ Yes ☐ No ☐ Unknown ■ Evidence of having received clinical care or medication for Bipolar Disorder:			
Yes No Unknown	tl		

nent

E.	PT:	SD Yes No Unknown
•	E۱	vidence of having received clinical care or medication for PTSD: 🗌 Yes 🔲 No 🔲 Unknown
	Εν	kiety Disorder ☐ Yes ☐ No ☐ Unknown vidence of having received clinical care or medication for Anxiety Disorder: ☐ Yes ☐ No ☐ Unknown
G.	Ne	urocognitive Disorder 🗆 Yes 🗆 No 🗀 Unknown
Н.	Sui	cide Attempt or Ideation
	a.	Within past 12 months
	b.	Ever
	C.	No indication from medical record or provider

. Liver disease:	
1. Chronic elevation of liver transaminases \square Yes \square No \square Unknown	
2. Chronic HBV infection 🗆 Yes 🗆 No 🗀 Unknown	
3. Chronic-HCV infection ever* Yes No Unknown	
Cured Yes No Unknown If yes, date of sustained virologic response (SVR)/_/ MM/ DD/ YYYY If decedent had been cured but was re-infected at time of death, please indicate hepatitis C infection in	
section 7 part C	
1. HDV infection ☐ Yes ☐ No ☐ Unknown	
5. History of previous liver decompensation \square Yes \square No \square Unknown	
6. Clinical signs of liver failure in the 4 weeks before death \square Yes \square No \square Unknown	
7. Liver fibrosis staging available (ever) ☐ Yes ☐ No ☐ Unknown	
f Yes, please indicate: • The date of most recent biopsy/ non-invasive fibrosis testing/Fibroscan / / MM/ DD/ YYYY	epa
The stage of fibrosis (0-4): and/or Fibroscan results: kPa	THE

J. Non-AIDS defining cancer ☐ Yes ☐ No ☐ Unknown		
If yes specify:		
i. Type		
ii. Date of diagnosis//		
MM/ DD/ YYYY		
K. Chronic Kidney Disease ☐ Yes ☐ No ☐ UnknownStage:		
Chronic hemodialysis ☐ Yes ☐ No ☐ Unknown		
L: Opportunistic Illnesses and Date of Diagnosis		
Illness Date (MM/YYYY)		



Section 5: ART and laboratory values prior to death

A. Has the patient EVER received ART Yes No Unknown
If YES, when was ART started (in months before death):
$\square \le 1$ month before $\square \le 3$ months before $\square \le 6$ months before \square More than 6 months before
B. Did the patient receive ART at the time of death? Yes No Unknown o If No, Date of stopping (MM/DD/YYYY)
C. Laboratory values (please complete all fields where data is available)

Laboratory values	Time	Value	Unit	Date MM/DD/YYY
HIV RNA	Most recent at time of stopping ART		Copies/mL	
	2 Most recent prior to death.		Copies/mL	
CD4+ cell count	Most recent prior to last stopping ART		Cells/mm3	
	Most recent prior to death		Cells/mm3	
	3. Nadir CD4 count		Cells/mm3	
Hemoglobin	Most recent prior to death		/	

Section 6: Hospitalizations in the 12 months prior to death

Name of hospital	Date of hospitalization (MM/DD/YYYY)	Primary and secondary discharge diagnoses



Section 7: Cause of death

C. Please complete the table below by recording all or injuries that the patient had at the time of death	•
B. Was the death unexpected? ☐ Yes ☐ No	Unknown
A. Was the death sudden? ☐ Yes ☐ No ☐	Unknown

Illness / Condition / Injury	Date of onset	Certa	inty of diagr	nosisa
(text)	MM/DD/YY	Definite	Likely	Possible
1.				
2.				
3.				
4.				
5.				
6.				
7.				
8.				
9.				

^aCertainty of Diagnosis: Definite=95-100% certainty, Likely=80-95% certainty, Possible=50-80% certainty

Department of Health

Cause of death Cont.

D. Brief narrative of the sequence of events leading to death (please include means of diagnosis of illnesses):
E. In summary, the causal relation between the conditions leading to death was (complete this section with the corresponding number from table C above):
Condition that directly caused death (immediate cause):
Due to or as a consequence of:
3. Due to or as a consequence of:
4. Condition that initiated the train of morbid events (the underlying condition)

Cause of death Cont.

F. Was the death related to immunodeficiency?

Was the underlying or contributing cause of death a CDC C disease or Hodgkin's Lymphoma?		
☐Yes ☐No ☐Unk	known	
f No, do you consider the	death to be related to immunodeficiency? (Please refer to the algorithm in the	
☐ Yes, definitively	Comments:	
Yes, likely		
Yes, possibly		
☐ No, assumed not		
☐ No, definitely not		

Section 8: Post-mortem/Autopsy

A. Has autopsy been performed: Yes No Unknown	
B. Did the autopsy reveal any evidence of substance use at time	of death?
☐ Yes, with the agent:	. □No □Unknown
Please include the full autopsy and toxicology reports if availabl the findings from the autopsy report.	le and provide a <u>brief summary</u> of

Post-mortem/Autopsy

C. Has a verbal autopsy been performed? \square Yes	□No□	Unknown	
Please include the verbal autopsy report, if availa from the verbal autopsy	ble, and pro	vide a brief summary	of the findings

Section 9: Adverse effects of medical treatment

A. Was the death considered to be related to a medical treatment? \square Yes \square No \square Possibly
B. The suspected relation was to: Antiretroviral treatment
Please provide a brief narrative of the suspected association including the name of the medication and the date of starting:

Sign-off

Completed by: Name (in print)
Position: □ Physician □ Nurse □ Other, describe
Directly involved in the medical care of the patient around the time of death? \Box Yes \Box No
Date (MM/DD/YYYY): Signature:
Reviewed by (if applicable): Name (in print)
Position: Physician Nurse Other, describe
Directly involved in the medical care of the patient around the time of death? \Box Yes \Box No
Date (MM/DD/YYYY): Signature:

The data abstraction can be performed by anyone at the facility with access to the patient's medical records, but the form must be reviewed by a clinician, if not completed by one to begin with.



Next Steps

- Methodology, Analysis and Access to Care subgroups will meet and discuss further aspects of the review process and data analysis
- Full guidance on the Mortality Review will be completed in early December, with sufficient time for distribution by mid-month.
- Webinars on the Mortality Review will be hosted in late December or early January

Questions and comments can be direct to Leah Hollander (leah.hollander@health.ny.gov)

